October 15, 2024
1 min learn
Key takeaways:
- IGA 0/1 was reached by 59% and 53% of dupilumab-naïve and dupilumab-experienced sufferers, respectively, at 9 months.
- Of the respective teams, 70% and 100% reported significant high quality of life enhancements. .
Practically half of sufferers with head and neck atopic dermatitis who had been handled with tralokinumab reported illness clearance after 9 months, based on a presentation on the European Academy of Dermatology and Venereology Congress.
“That is oftentimes considered probably the most difficult areas to deal with,” April W. Armstrong, MD, MPH, professor and chief of dermatology at College of California, Los Angeles, stated throughout her presentation on TRACE, a noninterventional, single cohort, real-world, 12-month research.
Practically half of sufferers with head and neck atopic dermatitis who had been handled with tralokinumab reported illness clearance after 9 months. Picture: Adobe Inventory.
Within the research, researchers noticed 824 tralokinumab-treated grownup sufferers with AD, 655 of which had AD on the top and neck.
“Total, within the cohort of sufferers throughout a number of completely different international locations in the true world beginning with tralokinumab, about 80% can have some type of head and neck atopic dermatitis,” Armstrong stated, emphasizing the significance of discovering remedy choices for this space.
Amongst these 655 sufferers, 501 had been dupilumab-naïve. The presentation touched on interim knowledge by 9 months of remedy.
Outcomes confirmed that after 3 months of remedy, the proportion of sufferers reporting head and neck AD decreased from 100% to 67% throughout affected person teams. By month 6 and 9, these proportions decreased additional to 58% and 52%, respectively.
IGA 0/1 was reached by 59% and 53% of dupilumab-naïve and dupilumab-experienced sufferers, respectively, on the finish of 9 months. A 2-point enchancment in IGA-assessed illness severity was additionally achieved by 75% and 63% of dupilumab-naïve and dupilumab-experienced sufferers in the identical timeframe.
All dupilumab-experienced sufferers reported a significant enchancment of their high quality of life by month 9 in contrast with 70% of dupilumab-naïve sufferers. Related proportions of sufferers in each teams reported enchancment in patient-reported eczema management by month 9 (46% and 44%).
Sources/Disclosures
Collapse
Armstrong AW, et al. Actual-world effectiveness of tralokinumab in adults with atopic dermatitis: Interim knowledge on enhancements in sufferers with head and neck atopic dermatitis after as much as 9 months of remedy within the TRACE research. Introduced at: European Academy of Dermatology and Venereology Congress; Sept. 25-28, 2024; Amsterdam.
Disclosures:
Armstrong reviews serving as an investigator and/or advisor to AbbVie, Almirall, Arcutis, Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte Company, Janssen, LEO Pharma A/S, Lilly, ModMed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Solar Pharma and UCB.
